Kazia Therapeutics Ltd
ASX:KZA
Kazia Therapeutics Ltd
Kazia Therapeutics Ltd. engages in the development of pharmaceutical drug. The company is headquartered in Sydney, New South Wales. The firm collaborates with clinicians, scientists, and researchers across the world for the development of cancer treatment. The Company’s product candidates include Paxalisib and EVT801. Paxalisib (GDC-0084) is invented by Genentech, Inc (South San Francisco, CA). Genentech, Inc is a developer of new cancer medicines across the world. The firm entered into a license agreement with Genentech. EVT801 targets angiogenesis, the formation of new blood vessels around a tumor. EVT801 is invented by Sanofi SA (Paris, France), and licensed to Evotec SE (Hamburg, Germany). The firm entered into a license agreement with Evotec. EVT801 is ready for Phase I clinical trial.
Kazia Therapeutics Ltd. engages in the development of pharmaceutical drug. The company is headquartered in Sydney, New South Wales. The firm collaborates with clinicians, scientists, and researchers across the world for the development of cancer treatment. The Company’s product candidates include Paxalisib and EVT801. Paxalisib (GDC-0084) is invented by Genentech, Inc (South San Francisco, CA). Genentech, Inc is a developer of new cancer medicines across the world. The firm entered into a license agreement with Genentech. EVT801 targets angiogenesis, the formation of new blood vessels around a tumor. EVT801 is invented by Sanofi SA (Paris, France), and licensed to Evotec SE (Hamburg, Germany). The firm entered into a license agreement with Evotec. EVT801 is ready for Phase I clinical trial.
